Genetic engineering concept. Medical science. Scientific Laboratory.

Blog

image-

Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing

Posted on

STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of […]

Read More email

image-

APDN Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

Posted on

STONY BROOK, N.Y. and ROME, ITALY – June 7, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated […]

Read More email

image-

APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Posted on

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA Vaccine candidate induced neutralizing titers in 100% of trial cohort Based on positive study results, companies plan to accelerate […]

Read More email

image-

Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

Posted on

COVID Feline Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse ModelsClinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines STONY BROOK, N.Y. & ROME. March 2, 2021. Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase […]

Read More email

image-

APDN Develops Linear DNA Veterinary COVID-19 Vaccine

Posted on

Applied DNA Achieves Program Milestone in Development of  Linear DNA Veterinary COVID-19 Vaccine – Qualifies Freeze-Dried Version of LinearDNA™ COVID-19 Vaccine Candidate Ahead of Initiation of Feline Clinical Trial – –  Reconstituted Vaccine Candidate Demonstrates Potency, Validating Easy Shipment in Dry State – – Feline Clinical Trial On-Track to Begin by March 31, 2021 – […]

Read More email

image-

APDN, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate

Posted on

Trial Redesigned to Accelerate Development of Clinical Path to Potential USDA APHIS Conditional License for Commercial Veterinary Sales STONY BROOK, N.Y. – November 30, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise […]

Read More email

image-

APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

Posted on

STONY BROOK, N.Y. – November 2, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, […]

Read More email

image-

APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

Posted on

STONY BROOK, N.Y. – September 16, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, preclinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it and Evvivax, S.R.L., a spin-out of Takis Biotech […]

Read More email

image-

APDN Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing

Posted on

Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA™ Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA STONY BROOK, N.Y. – August 17, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader […]

Read More email

image-

APDN and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19

Posted on

Demonstrates Evidence of Production of Antibodies and T Cell Responses in Mice: Shows Strong Antibody Responses, Activation of Sustainable T-Cell Responses, Presence of IgG in Lungs STONY BROOK, N.Y. – July 17, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, […]

Read More email